Mustafa Ozkaya, Muhammed Fatih Simsekoglu, Goktug Kalender, Kadir Can Sahin, Iclal Gurses
BACKGROUND: Thanks to technological advances, prostate cancer (PCa) can be diagnosed at a younger age. It is known that most of these patients are in the low-intermediate risk group, and the histological grade of the tumor increases in half of those undergoing radical prostatectomy (Rp) compared to their diagnostic biopsies. This is especially important in terms of active surveillance (AS) and/or the timely evaluation of curative treatment options in patients diagnosed at an early age...
May 27, 2024: Prostate
Edoardo Beatrici, Marco Paciotti, David-Dan Nguyen, Dejan K Filipas, Zhiyu Qian, Giovanni Lughezzani, Danesha Daniels, Stuart R Lipsitz, Adam S Kibel, Alexander P Cole, Quoc-Dien Trinh
BACKGROUND: The objective of this study was to quantify disparities in cancer treatment delivery between minority-serving hospitals (MSHs) and non-MSHs for breast, prostate, nonsmall cell lung, and colon cancers from 2010 to 2019 and to estimate the impact of improving care at MSHs on national disparities. METHODS: Data from the National Cancer Database (2010-2019) identified patients who were eligible for definitive treatments for the specified cancers. Hospitals in the top decile by minority patient proportion were classified as MSHs...
May 27, 2024: Cancer
Tenaw Tiruye, David Roder, Liesel M FitzGerald, Michael O'Callaghan, Kim Moretti, Gillian E Caughey, Kerri Beckmann
AIM: To assess the impact of comorbidities on prostate cancer mortality. METHODS: We studied 15,695 South Australian men diagnosed with prostate cancer between 2003 and 2019 from state-wide administrative linked data sets. Comorbidity was measured 1-year before prostate cancer diagnosis using Rx-Risk, a medication-based comorbidity index. Flexible parametric competing risk regression was used to estimate the independent association between comorbidities and prostate cancer-specific mortality...
May 26, 2024: Prostate
Matteo Ferro, Felice Crocetto, Evelina La Civita, Mariano Fiorenza, Giuseppe Jannuzzi, Gianluigi Carbone, Rosa Sirica, Enrico Sicignano, Giovanni Pagano, Ciro Imbimbo, Daniela Terracciano
BACKGROUND: There is a strong clinical need to fill the gap of identifying clinically significant prostate cancer (csPCa) in men with prostate-specific antigen (PSA) gray zone values. Promising, but not definitive results have been obtained using PSA derivatives such as prostate health index (PHI) and PHI density (PHID) and the percentage (-2)proPSA/free PSA (%p2PSA/fPSA). Thus, this study aimed to compare the diagnostic value of PHI, PHID, %proPSA/fPSA, and (-2)proPSA/freePSA density (-2pPSA/fPSAD) for csPCa in the patients with PSA within 2-10 ng/mL...
May 26, 2024: Prostate
James Y Dai, E Georg Luebeck, Ellen T Chang, Christina A Clarke, Earl A Hubbell, Nan Zhang, Stephen W Duffy
BACKGROUND: Late-stage cancer incidence has been proposed as an early surrogate for mortality in randomized controlled trials (RCTs) of cancer screening; however, its validity has not been systematically evaluated across screening RCTs of different cancers. METHODS: We conducted a meta-regression analysis of cancer screening RCTs that reported both late-stage cancer incidence and cancer mortality. Based on a systematic literature review, we included 33 RCTs of screening programs targeting seven cancer types, including lung ( n  = 12), colorectal ( n  = 8), breast ( n  = 5), and prostate ( n  = 4), among others...
May 26, 2024: Journal of Medical Screening
Erika Di Zazzo, Biagio Barone, Felice Crocetto
No abstract text is available yet for this article.
May 27, 2024: Journal of Basic and Clinical Physiology and Pharmacology
Krishana Kumar Sharma, Mohd Moshin, Piyush Mittal, Zeeshan Ali, Nishat Fatma, Prashant Upadhyay, Ritu Gupta, Anurag Verma, Gajendra Kumar
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. There may be more than a million instances of hepatocellular carcinoma by 2025, making it a persistent concern for global health. The most common form of hepatocellular carcinoma accounts for more than 90% of cases. There is no known cure for hepatocellular carcinoma, which is usually detected late in life. Unlike most other common malignancies, such as lung, prostate, and breast cancers, where mortality rates are declining, rates of death are rising by around 2-3% every year...
May 23, 2024: Current Pharmaceutical Design
Md Mozibullah, Hadieh Eslampanah Seyedi, Marina Khatun, Md Solayman
BACKGROUND: N-ras protein is encoded by the NRAS gene and operates as GDP-GTP-controlled on/off switching. N-ras interacts with cellular signaling networks that regulate various cellular activities including cell proliferation and survival. The nonsynonymous single nucleotide polymorphism (nsSNPs)-mediated alteration can substantially disrupt the structure and activity of the corresponding protein. N-ras has been reported to be associated with numerous diseases including cancers due to the nsSNPs...
June 2024: Journal, Genetic Engineering & Biotechnology
Caroline A Thompson, Paige Sheridan, Eman Metwally, Sharon Peacock Hinton, Megan A Mullins, Ellis C Dillon, Matthew Thompson, Nicholas Pettit, Allison W Kurian, Sandi L Pruitt, Georgios Lyratzopoulos
BACKGROUND: Internationally, 20-50% of cancer is diagnosed through emergency presentation, which is associated with lower survival, poor patient experience, and socioeconomic disparities, but population-based evidence about emergency diagnosis in the U.S. is limited. We estimated Emergency Department (ED) involvement in the diagnosis of cancer in a nationally representative population of older US adults, and associations with sociodemographic, clinical, and tumor characteristics. METHODS: We analyzed SEER-Medicare data for Medicare beneficiaries (≥66 years old) diagnosed with female breast, colorectal, lung and prostate cancers (2008-2017), defining their earliest cancer-related claim as their index date, and patients who visited the ED 0-30 days before their index date to have "ED involvement" in their diagnosis, with stratification as 0-7 or 8-30 days...
May 25, 2024: JNCI Cancer Spectrum
Andrew W Hahn, Efstratios Koutroumpakis, Vivek Narayan, Ana Aparicio
No abstract text is available yet for this article.
May 25, 2024: Prostate Cancer and Prostatic Diseases
Yusuke Takanashi, Tomoaki Kahyo, Keigo Sekihara, Akikazu Kawase, Mitsutoshi Setou, Kazuhito Funai
Cancer prognosis remains a critical clinical challenge. Lipidomic analysis via mass spectrometry (MS) offers the potential for objective prognostic prediction, leveraging the distinct lipid profiles of cancer patient-derived specimens. This review aims to systematically summarize the application of MS-based lipidomic analysis in prognostic prediction for cancer patients. Our systematic review summarized 38 studies from the past decade that attempted prognostic prediction of cancer patients through lipidomics...
May 25, 2024: Lipids in Health and Disease
Beihe Wang, Jian Pan, Tingwei Zhang, Xudong Ni, Yu Wei, Xiaomeng Li, Bangwei Fang, Xiaoxin Hu, Hualei Gan, Junlong Wu, Hongkai Wang, Dingwei Ye, Yao Zhu
BACKGROUND: The proposed trial is to examine the feasibility of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-guided cytoreduction plus apalutamide and androgen deprivation therapy (ADT) for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) at oligometastatic state. METHODS: CHAMPION (NCT05717582) is an open-label, single-arm, phase II trial, planning to enroll newly diagnosed mHSPC cases with oligometastases (≤ 10 distant metastatic sites in conventional imaging)...
May 25, 2024: BMC Cancer
Brian D Sleeman, Iain W Stewart
This paper develops a theory for anaphase in cells. After a brief description of microtubules, the mitotic spindle and the centrosome, a mathematical model for anaphase is introduced and developed in the context of the cell cytoplasm and liquid crystalline structures. Prophase, prometaphase and metaphase are then briefly described in order to focus on anaphase, which is the main study of this paper. The entities involved are modelled in terms of liquid crystal defects and microtubules are represented as defect flux lines...
May 23, 2024: Mathematical Biosciences
Lin Lin, Eric Lu, Josh Yurasits, Joanna Mercado, Megan Myers, Stuart Holden, Brian Shuch
OBJECTIVE: To meet the increasing demands of genetic risk assessment for genitourinary cancers due to expanded clinical guidelines, we established an academic/industry partnership to create a streamlined workflow to overcome the barriers to access to care. MATERIALS AND METHODS: Genome Medical offers multilingual genetic counseling. A pilot program evaluated patients at risk for hereditary genitourinary syndromes. Between 1/1/20 and 07/01/22, all patients in need of germline testing were offered hybrid in-clinic telehealth pre-test counseling and when indicated, genetic testing...
May 23, 2024: Urology
Mengyao Li, Xuying Zhang, Kailei Chen, Yang Miao, Yaxin Xu, Yishuo Sun, Mengxian Jiang, Mengcao Liu, Yan Gao, Xiaoxia Xue, Xuelian Li
Alcohol consumption significantly impacts disease burden and has been linked to various diseases in observational studies. However, comprehensive meta-analyses using Mendelian randomization (MR) to examine drinking patterns are limited. We aimed to evaluate the health risks of alcohol use by integrating findings from MR studies. A thorough search was conducted for MR studies focused on alcohol exposure. We utilized two sets of instrumental variables-alcohol consumption and problematic alcohol use-and summary statistics from the FinnGen consortium R9 release to perform de novo MR analyses...
May 17, 2024: Nutrients
Leticia Santos Pimentel, Luciana Machado Bastos, Luiz Ricardo Goulart, Lígia Nunes de Morais Ribeiro
Since prostate cancer (PCa) relies on limited therapies, more effective alternatives are required. Essential oils (EOs) and their bioactive compounds are natural products that have many properties including anticancer activity. This review covers studies published between 2000 and 2023 and discusses the anti-prostate cancer mechanisms of the EOs from several plant species and their main bioactive compounds. It also provides a critical perspective regarding the challenges to be overcome until they reach the market...
April 24, 2024: Pharmaceutics
Lei Wang, Chao-Cheng Chen, Zhengxing Zhang, Hsiou-Ting Kuo, Chengcheng Zhang, Nadine Colpo, Helen Merkens, François Bénard, Kuo-Shyan Lin
Gastrin-releasing peptide receptor (GRPR) is overexpressed in various cancers and is a promising target for cancer diagnosis and therapy. However, the high pancreas uptake and/or metabolic instability observed for most reported GRPR-targeted radioligands might limit their clinical applications. Our group recently reported a GRPR-targeted antagonist tracer, [68 Ga]Ga-TacsBOMB2 ([68 Ga]Ga-DOTA-Pip-D-Phe6 -Gln7 -Trp8 -Ala9 -Val10 -Gly11 -His12 -Leu13 ψThz14 -NH2 ), which showed a minimal pancreas uptake in a preclinical mouse model...
May 11, 2024: Pharmaceuticals
Kirti S Prabhu, Serah Jessy, Shilpa Kuttikrishnan, Farina Mujeeb, Zahwa Mariyam, Ummu Habeeba, Nuha Ahmad, Ajaz A Bhat, Shahab Uddin
The growing global burden of malignant tumors with increasing incidence and mortality rates underscores the urgent need for more effective and less toxic therapeutic options. Herbal compounds are being increasingly studied for their potential to meet these needs due to their reduced side effects and significant efficacy. Pristimerin (PS), a triterpenoid from the quinone formamide class derived from the Celastraceae and Hippocrateaceae families, has emerged as a potent anticancer agent. It exhibits broad-spectrum anti-tumor activity across various cancers such as breast, pancreatic, prostate, glioblastoma, colorectal, cervical, and lung cancers...
April 30, 2024: Pharmaceuticals
Mei-Chi Su, Adam M Lee, Weijie Zhang, Danielle Maeser, Robert F Gruener, Yibin Deng, R Stephanie Huang
Metastatic castration-resistant prostate cancer (mCRPC) remains a deadly disease due to a lack of efficacious treatments. The reprogramming of cancer metabolism toward elevated glycolysis is a hallmark of mCRPC. Our goal is to identify therapeutics specifically associated with high glycolysis. Here, we established a computational framework to identify new pharmacological agents for mCRPC with heightened glycolysis activity under a tumor microenvironment, followed by in vitro validation. First, using our established computational tool, OncoPredict, we imputed the likelihood of drug responses to approximately 1900 agents in each mCRPC tumor from two large clinical patient cohorts...
April 29, 2024: Pharmaceuticals
Beliz Bahar Karaoğlan, Yüksel Ürün
Human papillomavirus (HPV), an oncogenic DNA virus, is the most common sexually transmitted virus and significant public health concern globally. Despite the substantial prevalence of HPV infection among men, routine testing remains elusive due to the lack of approved HPV tests and the complexity of detection methods. Various studies have explored the link between HPV and genitourinary cancers, revealing different associations influenced by geographic variation, histological subtype and methodological differences...
April 25, 2024: Viruses
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.